Copyright
©The Author(s) 2021.
World J Diabetes. Aug 15, 2021; 12(8): 1267-1281
Published online Aug 15, 2021. doi: 10.4239/wjd.v12.i8.1267
Published online Aug 15, 2021. doi: 10.4239/wjd.v12.i8.1267
Figure 1 Changes in body weight of mice in each group.
aP < 0.05. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 2 Changes in liver and fat weights of mice in each group.
A: Changes in liver weight of mice in each group; B: Changes in fat weight of mice in each group. aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 3 Effect of decabromodiphenyl ether on mouse liver tissue morphology (Hematoxylin and eosin, × 400).
A: High dose group; B: Medium-high dose group; C: Medium dose group; D: Medium-low dose group; E: Low dose group; and F: Control group. The red circles refer to the inflammatory cells.
Figure 4 Comparisons of serum leptin and adiponectin levels of mice in each group.
A: Comparisons of serum leptin levels of mice in each group; B: Comparisons of serum adiponectin levels of mice in each group. aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 5 Comparison of adiponectin protein expression in liver tissue of mice in each group.
A: Quantification of the data presented in B; B: Immunoblots of each group. aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 6 Comparison of leptin protein expression in liver tissue of mice in each group.
A: Quantification of the data presented in B; B: Immunoblots of each group. aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 7 Comparison of peroxisome proliferators activated receptor-γ protein expression in liver tissue of mice in each group.
A: Quantification of the data presented in B; B: Immunoblots of each group. aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 8 Comparison of adiponectin protein expression in adipose tissue of mice in each group.
A: Quantification of the data presented in B; B: Immunoblots of each group. aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 9 Comparison of leptin protein expression in adipose tissue of mice in each group.
A: Quantification of the data presented in B; B: Immunoblots of each group. aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
Figure 10 Comparison of peroxisome proliferator activated receptor-γ protein expression in adipose tissue of mice in each group.
A: Quantification of the data presented in B; B: Immunoblots of each group; aP < 0.05 compared with the control group; bP < 0.05 compared with the medium dose group; and cP < 0.05 compared with the low dose group. H: High dose group; MH: Medium-high dose group; M: Medium dose group; ML: Medium-low dose group; L: Low dose group; C: Control group.
- Citation: Alimu A, Abudureman H, Wang YZ, Li MY, Wang JS, Liu ZL. Decabromodiphenyl ether causes insulin resistance and glucose and lipid metabolism disorders in mice. World J Diabetes 2021; 12(8): 1267-1281
- URL: https://www.wjgnet.com/1948-9358/full/v12/i8/1267.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i8.1267